Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.
Performance of psychedelic public companies this past week.
Algernon Pharmaceuticals ($AGN | $AGNPF) received approval to conduct a Phase I clinical study for their DMT-based psychedelic compound, AP-188, for the treatment of stroke. Algernon's preclinical study showed that DMT increased growth of neurons by 40%. Press Release
Awakn Life Sciences ($AWKN | $AWKNF) signed a drug development agreement with Catalent, a global leader in enabling biopharma, cell, gene, and consumer health, to investigate a proprietary formulation and optimized delivery route for MDMA using Catalent's proprietary Zydis orally disintegrating tablet technology. Press Release
Nova Mentis Life Science ($NOVA | $NMLSF) completed production of psilocybin microdose capsules in collaboration with the Toronto Institute of Pharmaceutical Technology. Nova Mentis is currently preparing to submit a clinical trial application for a Phase IIa study evaluating psilocybin microdose therapy for fragile X syndrome. Press Release
Sunstone Therapies (Private) an organization dedicated to the treatment of the psychological effects of cancer has partnered with MAPS to conduct a clinical trial focused on the safety and tolerability of MDMA-assisted therapy for patients with treatment-resistant PTSD. Press Release
Revive Therapeutics ($RVV | $RVVTF) provided an update on their Phase I/II clinical study of oral psilocybin as a potential treatment of methamphetamine use disorder and the development of their proprietary oral psilocybin thin film strip product. Revive's Phase I/II clinical study received both FDA and Institutional Review Board approval. Press Release
Seelos Therapeutics ($SEEL) announced the participation of Acadia Healthcare ($ACHC) in their Phase II clinical trial of SLS-002, an intranasal racemic ketamine, for Acute Suicidal Ideation and Behavior in patients with MDD. Acadia Healthcare operates a network of nearly 240 behavioral health facilities in the United States. Press Release
Braxia Scientific ($BRAX | $BRAXF) successfully launched KetaMD in Florida and completed initial at-home ketamine treatments. KetaMD is an innovative telemedicine platform, that provides access to safe, affordable, at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and PTSD. Press Release
The Washington Post: Ketamine For Depression: What It Feels Like And Who It Can Help
Wall Street Journal: Investors Bet Ketamine Treatment Will Revolutionize Mental-Health Care
Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.